Compare Halozyme Therapeutics Inc. Common Stock (HALO) vs TKO Group Holdings Inc (TKO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Halozyme Therapeutics Inc. Common Stock vs TKO Group Holdings Inc — how do they compare? Halozyme Therapeutics Inc. Common Stock trades at $110.42 (market cap $12.58B), while TKO Group Holdings Inc trades at $178.01 (market cap $13.28B). The key difference: Halozyme Therapeutics Inc. Common Stock and TKO Group Holdings Inc are close in size by market cap, and TKO Group Holdings Inc pays a 1.74% dividend while Halozyme Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Halozyme Therapeutics Inc. Common Stock for 1 Days and TKO Group Holdings Inc for 30 Days on average.
| HALO | TKO | |
|---|---|---|
Market Cap | $12.58B | $13.28B |
Volume | 2,179,278 | 857,653 |
Sector | Health | Media |
52-Week High | $115.22 | $224.96 |
52-Week Low | $61.63 | $175.58 |
Typical Hold Time | 1 Days | 30 Days |
Enterprise Value | $14.49B | $17.64B |
Dividend Yield | — | 1.74% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TKO trades at $178.01, down 0.35% on the day, near its 52-week low of $174.58 (Defense World, 2026-10-02). The stock is technically bearish with mixed earnings history, including a Q2 2026 EPS miss. Revenue grew to $5.3B in 2026 with a net profit margin of 4.32%. A quarterly dividend of $0.79 is scheduled for payment on September 30, 2026.
Wall Street maintains a strong buy consensus (89% buy ratings) with a $227 price target, suggesting significant upside. Key risks include earnings volatility and competitive pressures in sports entertainment. Positive catalysts are media rights deals and live event momentum, but the stock faces near-term technical headwinds.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About Halozyme Therapeutics Inc. Common Stock
Halozyme Therapeutics develops drug-delivery technologies for biopharmaceutical companies. Its ENHANZE technology uses the rHuPH20 enzyme to support subcutaneous delivery of co-administered medicines.
Read more on HALO →About TKO Group Holdings Inc
TKO Group Holdings is a premium sports and entertainment company that serves as the parent entity for the Ultimate Fighting Championship (UFC) and World Wrestling Entertainment (WWE). Formed through a seismic merger orchestrated by Endeavor, TKO leverages a combined global fanbase of over 1 billion to drive massive revenue through media rights, global live events, and a unified sponsorship platform, effectively monopolizing the professional combat sports landscape.
Read more on TKO →
